Revolutionary Cocktail: Imfinzi + Imjudo Combo Prolongs Liver Cancer Survival

Photo of author

By Ronald Tech

AstraZeneca company office building
  • New study results have revealed that the combination of AstraZeneca’s Imfinzi (durvalumab) and Imjudo (tremelimumab) offers a remarkable long-term survival benefit for individuals battling unresectable hepatocellular carcinoma (HCC) without prior systemic therapy or eligibility for localized treatment.
  • Analysis showcased at the European Society of Medical Oncology demonstrates that incorporating a single priming dose of Imjudo alongside Imfinzi slashed the risk of death by an impressive 24% when compared to Bayer’s Nexavar (sorafenib). Noteworthy, approximately 19.6% of patients receiving this groundbreaking duo were still alive after five years, a stark contrast to the 9.4% survival rate observed in those on Nexavar.


See also  Market Clubhouse Morning Memo - February 20th, 2024 Market Clubhouse Morning Market Analysis - February 20th, 2024